Paul R. Bohjanen

Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis

David R. Boulware, David B. Meya, Conrad Muzoora et al. · New England Journal of Medicine · 2014 · 493 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +13

Three functional variants of IFN regulatory factor 5 ( <i>IRF5</i> ) define risk and protective haplotypes for human lupus

Robert Graham, Chieko Kyogoku, Irina Vlasova-St. Louis et al. · Proceedings of the National Academy of Sciences · 2007 · 456 citations · Full text

Life Sciences, Genetics, Immunology +17

Higher Levels of CRP, D-dimer, IL-6, and Hyaluronic Acid Before Initiation of Antiretroviral Therapy (ART) Are Associated With Increased Risk of AIDS or Death

David R. Boulware, Katherine Huppler Hullsiek, Camille E. Puronen et al. · The Journal of Infectious Diseases · 2011 · 315 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy

Andrew Kambugu, David B. Meya, Joshua Rhein et al. · Clinical Infectious Diseases · 2008 · 305 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

Cost‐Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV‐Infected Persons with a CD4⁺Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource‐Limited Settings

David B. Meya, Yukari C. Manabe, Barbara Castelnuovo et al. · Clinical Infectious Diseases · 2010 · 303 citations · Full text

Public Health, Infectious Diseases, Pharmacoeconomics +17